Targeted Therapies and Lung Cancer

From Reuters

Tecentriq Plus Chemo

March 20, 2018: A late-stage study shows Roche’s immunotherapy Tecentriq plus chemotherapy cut the risk of disease worsening or death in first-line treatment of people with a type of advanced lung cancer.

“Squamous non-small cell lung cancer is difficult to treat and there have been limited new treatment options over the last few decades,” said Sandra Horning, Roche’s chief medical officer, adding the company was still awaiting overall survival data in its Impower131 study.

More information on Squamous non-small cell lung cancer.

Learn more